Drug Trial Radar · NCT01085136
LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
Last checked: Nov 19, 2026Latest source record: Apr 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,154
Actual
Start
Feb 2010
Primary completion
Oct 2013
Study completion Jan 2016
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this randomized, open-label, active-controlled, multi-center trial is to determine the efficacy of BIBW 2992 given as an add-on to chemotherapy in patients with NSCLC Stage IIIb or IV progressing after BIBW 2992 monotherapy compared to chemotherapy alone in this patient population. Patients on both treatment arms will receive best supportive care in addition to study treatment. Patients enrolled into the trial will be treated and followed until death or lost to follow-up. Additional information on the health-related quality of life (HRQOL) will be collected.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
Investigator´s choice of chemotherapyDrug
BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
BIBW 2992Drug
BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (Part B)Time frame: From randomization until disease progression or death; Up to 32 months
Locations
97 sites in 23 countries. Site status is shown where the registry gives one.
Boehringer Ingelheim Investigational Site
Buenos Aires, Argentina
Boehringer Ingelheim Investigational Site
Kingswood, New South Wales, Australia
Boehringer Ingelheim Investigational Site
South Brisbane, Queensland, Australia
Boehringer Ingelheim Investigational Site
Box Hill, Victoria, Australia
Boehringer Ingelheim Investigational Site
Fitzroy, Victoria, Australia
Boehringer Ingelheim Investigational Site
Wodonga, Victoria, Australia
Boehringer Ingelheim Investigational Site
Salzburg, Austria
Boehringer Ingelheim Investigational Site
Aalst, Belgium
Boehringer Ingelheim Investigational Site
Brussels, Belgium
Boehringer Ingelheim Investigational Site
Duffel, Belgium
Boehringer Ingelheim Investigational Site
La Louvière, Belgium
Boehringer Ingelheim Investigational Site
Liège, Belgium
Boehringer Ingelheim Investigational Site
Middelheim, Belgium
Boehringer Ingelheim Investigational Site
Ottignies, Belgium
Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
Boehringer Ingelheim Investigational Site
Beijing, China
Boehringer Ingelheim Investigational Site
Changchun, China
Boehringer Ingelheim Investigational Site
Chengdu, China
Boehringer Ingelheim Investigational Site
Fuzhou, China
Boehringer Ingelheim Investigational Site
Guangzhou, China
Boehringer Ingelheim Investigational Site
Hangzhou, China
Boehringer Ingelheim Investigational Site
Nanjing, China
Boehringer Ingelheim Investigational Site
Shanghai, China
Boehringer Ingelheim Investigational Site
Helsinki, Finland
Boehringer Ingelheim Investigational Site
Bayonne, France
Boehringer Ingelheim Investigational Site
Caen, France
Boehringer Ingelheim Investigational Site
Dijon, France
Boehringer Ingelheim Investigational Site
La Tronche, France
Boehringer Ingelheim Investigational Site
Lyon, France
Boehringer Ingelheim Investigational Site
Paris, France
Boehringer Ingelheim Investigational Site
Saint-Herblain, France
Boehringer Ingelheim Investigational Site
Villejuif, France
Boehringer Ingelheim Investigational Site
Berlin, Germany
Boehringer Ingelheim Investigational Site
Essen, Germany
Boehringer Ingelheim Investigational Site
Esslingen am Neckar, Germany
Boehringer Ingelheim Investigational Site
Gauting, Germany
Boehringer Ingelheim Investigational Site
Hamburg, Germany
Boehringer Ingelheim Investigational Site
Hanover, Germany
Boehringer Ingelheim Investigational Site
Heidelberg, Germany
Boehringer Ingelheim Investigational Site
Mainz, Germany
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.